| Identification | Back Directory | [Name]
SBC110,736 | [CAS]
1629166-02-4 | [Synonyms]
SBC110,736
SBC-1107326
SBC110736;SBC 110736
N-(4-{[4-(4-Methylphenyl)-2-phenyl-1-piperazinyl]carbonyl}phenyl)acetamid
Acetamide, N-[4-[[4-(4-methylphenyl)-2-phenyl-1-piperazinyl]carbonyl]phenyl]- | [Molecular Formula]
C26H27N3O2 | [MDL Number]
MFCD30541539 | [MOL File]
1629166-02-4.mol | [Molecular Weight]
413.51 |
| Chemical Properties | Back Directory | [Boiling point ]
681.1±55.0 °C(Predicted) | [density ]
1.204±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO:64.0(Max Conc. mg/mL);154.77(Max Conc. mM) | [form ]
A crystalline solid | [pka]
14.77±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1[1]. | [in vivo]
SBC-110736 (male C57BL/6 mice) lowers cholesterol levels in mice that were fed high fat diet, showing a mean of 38% reduction in total cholesterol levels after two weeks relative to high fat diet animal levels and a mean 50% reduction toward return to regular diet cholesterol levels[1]. | [storage]
Store at -20°C | [References]
[1] Sherin Salaheldin Abdel-Meguid, et al. Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases. WO2014150395A1. |
|
|